With this approach we identified MDM2 ligase, coupled with inhibitors of the targets BCL2L1, BRD4, CDK9, PLK1 and MCL1 in stomach tumor tissue, as a therapeutic strategy. This evidence concerns the gene CDK9 and gastric neoplasm.